Martyn Lewis

Title: Martyn Lewis: Innovator in CAR-T Cell Technology

Introduction

Martyn Lewis is a notable inventor based in Danville, CA (US), recognized for his contributions to the field of biotechnology. He holds a patent that focuses on enhancing the efficacy of CAR-T cell therapies, specifically targeting the tumor antigen CD19. His innovative approach aims to improve patient outcomes in cancer treatment.

Latest Patents

Martyn Lewis holds a patent for "Flag tagged CD19-CAR-T cells." This invention provides chimeric antigen receptor (CAR)-T cells that are modified to express a CAR fusion protein. The fusion protein includes a single-chain variable fragment (scFv) that targets the tumor antigen CD19, a transmembrane domain, co-stimulatory domains, and an activating domain. Notably, the fusion protein incorporates a FLAG tag, which can be positioned at various locations within the scFv. The use of CD19-FLAG CAR-T cells has been shown to reduce cytokine levels, such as Interferon-γ, IL-2, and IL-6, compared to traditional CD19 CAR-T cells.

Career Highlights

Throughout his career, Martyn Lewis has worked with prominent companies in the biotechnology sector. He has been associated with Promab Biotechnologies, Inc. and Forevertek Biotechnology Co., Ltd. His work in these organizations has contributed significantly to advancements in CAR-T cell therapies and related technologies.

Collaborations

Martyn Lewis has collaborated with notable professionals in his field, including Lijun Wu and Vita Golubovskaya. These collaborations have fostered innovation and development in CAR-T cell research and applications.

Conclusion

Martyn Lewis is a distinguished inventor whose work in CAR-T cell technology has the potential to transform cancer treatment. His innovative patent and collaborations highlight his commitment to advancing biotechnology for improved patient care.